

JFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

AUG 19 2004

Docket No.
1059.00096

In Re Application Of: Hani Sabbah, et al.

U.S. PATENT & TRADEMARK OFFICE

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/700,032	11-03-03			1632	

Title: CARDIAC TRANSPLANTATION OF STEM CELLS FOR THE TREATMENT OF HEART FAILURE

Address to:
Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMISSION OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
1059.00096

AUG 19 2004

In Re Application: Hani Sabbah, et al.

U.S. PATENT & TRADEMARK OFFICE

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/700,032	11-03-03			1632	

Title: CARDIAC TRANSPLANTATION OF STEM CELLS FOR THE TREATMENT OF HEART

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 11-1449 as described below.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to
"Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" 8-17-04

(Date)

Signature of Person Mailing Correspondence

Connie Herty

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Kenneth I. Kohn, Reg. No. 30,955

KOHN & ASSOCIATES, PLLC

30500 Northwestern Highway, Suite 410

Farmington Hills, Michigan 48334

(248) 539-5050

Dated: August 17, 2004

cc:



Form PTO-1440 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 1059.00096		Application Number 10/ 700,032		
		Applicant Sabbah et al				
		Filing Date 11-3-03		Group Art Unit 1632		
		U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,666,828		Gusella			
	4,683,202		Mullis			
	4,801,531		Frossard			
	5,192,659		Smulson et al			
	5,272,057		Simons			
FOREIGN PATENT DOCUMENTS						
	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)						
	Beresford, J. N.: Osteogenic Stem Cells and the connective Stromal System of Bone and Marrow, <i>Clin. Orthop.</i> , 240:270,1989.					
	Burke and Olson, "Preparation of Clone Libraries in Yeast Artificial-Chromosome Vectors" in <i>Methods in Enzymology</i> , Vol. 194, "Guide to Yeast Genetics and Molecular Biology", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 17, pp. 251-270 (1991).					
	Capecchi, "Altering the genome by homologous recombination" <i>Science</i> 244:1288-1292 (1989).					
	Cregg JM, Vedick TS, Raschke WC: Recent Advances in the Expression of Foreign Genes in <i>Pichia pastoris</i> , <i>Bio/Technology</i> 11:905-910, 1993					
not available	Culver, 1998. Site-Directed recombination for repair of mutations in the human ADA gene. (Abstract) <i>Antisense DNA & RNA based therapeutics</i> , February, 1998, Coronado, CA.					
	Davies et al., "Targeted alterations in yeast artificial chromosomes for inter-species gene transfer", <i>Nucleic Acids Research</i> , Vol. 20, No. 11, pp. 2693-2698 (1992).					
	Gilboa, E, Eglitis, MA, Kantoff, PW, Anderson, WF: Transfer and expression of cloned genes using retroviral vectors. <i>BioTechniques</i> 4(6):504-512, 1986.					
	Huston et al, 1991 "Protein engineering of single-chain Fv analogs and fusion proteins" in <i>Methods in Enzymology</i> (JJ Langone, ed.; Academic Press, New York, NY) 203:46-88.					
	Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK, Goodell MA. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. <i>J Clin Invest</i> 2001 Jun;107(11):1395-402.					

	Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial chromosome", <i>Nature</i> , Vol. 362, pp. 255-261 (1993).
	Lamb et al., "Introduction and expression of the 400 kilobase <i>precursor amyloid protein</i> gene in transgenic mice", <i>Nature Genetics</i> , Vol. 5, pp. 22-29 (1993).
	Maltsev VA, Rohwedel J, Hescheler J, Wobus AM: Embryonic stem cells differentiate <i>in vitro</i> into cardiomyocytes representing sinusnodal, atrial and ventricular cell types. <i>Mechanisms of Development</i> , 1994; 191:41-50.
	Maltsev VA, Wobus AM, Rohwedel J, Bader M, Hescheler J. Cardiomyocytes differentiated <i>in vitro</i> from embryonic stem cells developmentally express cardiac-specific genes and ionic currents. <i>Circulation Research</i> , 1994; 75(2):233-244.
	Mernaugh and Mernaugh, 1995 "An overview of phage-displayed recombinant antibodies" in <i>Molecular Methods In Plant Pathology</i> (RP Singh and US Singh, eds.; CRC Press Inc., Boca Raton, FL) pp. 359-365.
	Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. <i>Nature</i> . 2001 Apr 5;410(6829):640-1.
	Pearson and Choi, <i>Expression of the human b-amyloid precursor protein gene from a yeast artificial chromosome in transgenic mice</i> . Proc. Natl. Acad. Sci. USA, 1993. 90:10578-82.
	Rothstein, "Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast" in <i>Methods in Enzymology</i> , Vol. 194, "Guide to Yeast Genetics and Molecular Biology", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 19, pp. 281-301 (1991).
	Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, Hawkins ET, Goldstein S. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. <i>American Journal of Physiology</i> . 1991; 260:H1379-84.
	Sabbah, HN. Apoptotic cell death in heart failure. <i>Cardiovasc Res</i> . 2000 45:704-712.
	Schedl et al., "A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice", <i>Nature</i> , Vol. 362, pp. 258-261 (1993).
	Strauss et al., "Germ line transmission of a yeast artificial chromosome spanning the murine α_1 (I) collagen locus", <i>Science</i> , Vol. 259, pp. 1904-1907 (1993).
	Wang JS, Shum-Tim D, Galipeau J, Chedrawy E, Eliopoulos N, Chiu RC. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. <i>J Thorac Cardiovasc Surg</i> . 2000.
EXAMINER	DATE CONSIDERED

PTO/SB/08 (2-92)
COMMERCE

Patent and Trademark Office; U.S. DEPARTMENT OF